CD274 and cancer: With regard to pathophysiological ensurance, various clinical studies have been conducted to provide empirical evidence for evaluating the effects of PD-1/PD-L1 inhibitors on esophageal or G/GEJ cancer—a cancer type with a low survival rate [6,8].